中科生物(01237.HK):預計2019年度虧損將大幅收窄
格隆匯3月5日丨中科生物(01237.HK)發佈公告,根據董事會現有資料,比較2018年度所錄得的虧損約人民幣1.849億元,集團預期於截至2019年12月31日止年度錄得的虧損將大幅減少。董事會認為,虧損減少主要由於2018年度集團已為其生產設施確認資產減值約人民幣1.393億元,而2019年度則無須再作出重大額外資產減值。
此外,在撇除2018止年度確認的資產減值的影響後,集團預期2019年度錄得的虧損將有所增加,主要由於美國自2019年5月起向部份中國出口商品徵收的關税由10%提高至25%,導致集團出口美國的木製品產品的利潤進一步率下跌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.